ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026
Impact of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk: real-world evidence from a retrospective cohort study.
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Bisphosphonate drug holidays can reduce rare adverse effects, but their skeletal impact is unclear. In this retrospective cohort study, ALN holiday caused modest BMD loss and BTMs rise without increased fracture risk; effects of ZOL holiday were minimal. This study suggests bisphosphonate drug holidays are safe for selected patients with regular monitoring. PURPOSE: Bisphosphonate (BP) drug holiday prevents rare adverse effects of BPs in osteoporotic patients, but its effect on bone mineral density (BMD), bone turnover markers (BTMs), and fracture risk is still unclear. This study aimed to investigate BMD/BTM variations and clinical fracture risk for patients undergoing BP drug holidays.
methodsIn this single-center retrospective cohort study, patients who received ≥4.5 years of alendronate (ALN) or ≥3 doses of zoledronate (ZOL) were included. BMD at the lumbar spine (LS), femoral neck (FN), and total hip (TH), BTMs, and 3-year fracture incidence were assessed between drug holiday (ALN: n = 71; ZOL: n = 20) and ongoing treatment groups (ALN: n = 59; ZOL: n = 47).
resultsCompared with ongoing ALN therapy, initiating drug holiday resulted in moderate declines in BMD at LS (-2.23%, 95% CI: -3.70% to -0.76%), TH (-1.62%, 95% CI: -2.68% to -0.56%), and FN (-1.89%, 95% CI: -3.49% to -0.28%) within 1 year. BTMs all rose significantly over 1 year, yet remained below pretreatment levels for at least 3 years. In contrast, there were no significant differences in BMD (1-year LS: -0.47%, 95% CI: -2.38% to 1.43%, TH: -1.07%, 95% CI: -2.77% to 0.64%) and BTM changes between ZOL groups at 1- and 2-year follow-up. No significant differences in clinical fragility fractures were observed between ALN groups (9.9% vs. 6.8%; HR 1.45) and ZOL groups (5% vs. 6.4%).
conclusionOur findings support that BP drug holidays are feasible for selected patients with adequate BMD. ZOL conferred more sustained skeletal protection than ALN, particularly at the LS, whereas ALN discontinuation was associated with earlier and more pronounced BMD decline and BTM elevation; annual monitoring of BMD and BTMs appears particularly important during the ALN drug holiday period.
Indexed as
Identifiers
42862289What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.